Sales increased by 15% in Danish kroner and by 11% in local currencies. -- Sales of modern insulins increased by 14% (11% in local currencies).
-- Victoza(R) sales of DKK 1,098 million (growth of 191% in local currencies).
-- Sales of NovoSeven(R) increased by 6% (4% in local currencies).
-- Sales in North America increased by 16% (14% in local currencies).
-- Sales in Region China increased by 34% (28% in local currencies).
Gross margin improved by 0.3 percentage points in local currencies, reflecting a favourable product mix development, but due to a negative currency effect, the gross margin declined by 0.2 percentage points to 80.1% compared to the first quarter of 2010.
Reported operating profit increased by 24% to DKK 5,418 million. Measured in local currencies, operating profit increased by approximately 20%.
Net profit increased by 23% to DKK 4,073 million. Earnings per share (diluted) increased by 26% to DKK 7.06.
Novo Nordisk has completed a pre-specified meta-analysis based on the Degludec phase 3a trial programme. The meta-analysis confirmed that Degludec is associated with a lower risk of hypoglycaemia compared to insulin glargine, both on the total number of confirmed hypoglycaemic events, and on the number of confirmed nocturnal hypoglycaemic events. Both findings are statistically significant.
The 2011 outlook remains unchanged: sales growth of 8-10% and operating profit growth of around 15%, both measured in local currencies.
Lars Rebien S0rensen, president and CEO, says: "We are encouraged by the continued double-digit sales growth driven by Victoza(R) and modern insulins. It strengthens our confidence in the company's long term growth prospects despite the near-term impact on sales growth from healthcare reforms in the US and other major markets, which is reflected in the 2011 outlook."
29 April 2011
Pediatric flu vaccination: Understanding low acceptance rates could help increase coverage
A study of H1N1 and seasonal influenza vaccination in a sample of black and Hispanic children in Atlanta found a low rate of vaccine acceptance among parents and caregivers. Only 36 percent of parents and caregivers indicated they would immunize children against H1N1, and 22 percent indicated their children received the seasonal influenza vaccine in the previous three months. The majority of children in the sample (71 percent) were from households with less than $40,000 in annual income. Researchers say this low level of vaccine coverage and acceptance highlights the importance of understanding individual and community concerns that influence parents' decisions to have their children vaccinated.
The study is published in the Vaccine Safety Supplement of the April issue of the journal Pediatrics.
Children aged six months through 18 years, and caregivers of children younger than six months, were among the stated high-priority groups for the 2009 H1N1 vaccine. More recently, the ACIP has recommended that all persons older than six months should be vaccinated annually against influenza.
The study found that parents who said they were concerned about influenza, were concerned about H1N1 disease, and had confidence in vaccines and their preventive abilities were more likely to accept vaccination.
Although income did not correlate with vaccine acceptance, parents without health insurance were more likely to say they would vaccinate their children against H1N1 than were parents with insurance. The authors speculated this is due to concern related to treatment cost among parents without insurance.
Safety issues were generally not cited as a factor influencing decisions, but perceived greater risk of exposure and illness for children from the H1N1 virus was cited as a reason for those accepting vaccination. Other factors contributing to acceptance included lack of confidence in the effectiveness of hand washing, masks, and quarantine approaches over the H1N1 vaccine as prevention methods, and having a desire to promote influenza vaccination in the community.
"The well-publicized risks to children of contracting the H1N1 virus may have outstripped vaccine safety concerns in this case," notes lead author Paula Frew, PhD. "This shows that more comprehensive education of minority parents with regard to disease risk may provide a boost to vaccination rates." Frew is assistant professor of medicine and director of community research in Emory University School of Medicine.
"Physicians have a central community leadership role in educating parents about the importance of influenza vaccination…" the authors write. "Moreover, our study results show parental confidence in the health departments to provide influenza vaccination compared with other community-based venues."
"Physician support of vaccination can help increase vaccine coverage, and community health departments are ideal locations for vaccine administration," says Frew.
**Source: Emory University
The study is published in the Vaccine Safety Supplement of the April issue of the journal Pediatrics.
Children aged six months through 18 years, and caregivers of children younger than six months, were among the stated high-priority groups for the 2009 H1N1 vaccine. More recently, the ACIP has recommended that all persons older than six months should be vaccinated annually against influenza.
The study found that parents who said they were concerned about influenza, were concerned about H1N1 disease, and had confidence in vaccines and their preventive abilities were more likely to accept vaccination.
Although income did not correlate with vaccine acceptance, parents without health insurance were more likely to say they would vaccinate their children against H1N1 than were parents with insurance. The authors speculated this is due to concern related to treatment cost among parents without insurance.
Safety issues were generally not cited as a factor influencing decisions, but perceived greater risk of exposure and illness for children from the H1N1 virus was cited as a reason for those accepting vaccination. Other factors contributing to acceptance included lack of confidence in the effectiveness of hand washing, masks, and quarantine approaches over the H1N1 vaccine as prevention methods, and having a desire to promote influenza vaccination in the community.
"The well-publicized risks to children of contracting the H1N1 virus may have outstripped vaccine safety concerns in this case," notes lead author Paula Frew, PhD. "This shows that more comprehensive education of minority parents with regard to disease risk may provide a boost to vaccination rates." Frew is assistant professor of medicine and director of community research in Emory University School of Medicine.
"Physicians have a central community leadership role in educating parents about the importance of influenza vaccination…" the authors write. "Moreover, our study results show parental confidence in the health departments to provide influenza vaccination compared with other community-based venues."
"Physician support of vaccination can help increase vaccine coverage, and community health departments are ideal locations for vaccine administration," says Frew.
**Source: Emory University
Study: Cotton swabs prove problematic for ear health
A study by Henry Ford Hospital shows a direct association between cotton swab use and ruptured eardrum. The study also shows that in most cases the rupture heals on its own and surgery is only necessary for the most severe cases.
"In the past, many otolaryngologists have wondered if surgery is really necessary to treat a ruptured eardrum. The results of this study show that 97 percent of cases healed on their own within two months, proving that most cases do not require surgery," says Ilaaf Darrat, M.D., an otolaryngologist at Henry Ford Hospital and co-author of the study.
The study is being presented April 29 at the Combined Otolaryngology Spring Meeting in Chicago.
More than half of patients seen in otolaryngology (ear, nose and throat) clinics, regardless of their primary complaint, admit to using cotton swabs to clean their ears. But if the cotton swab is pushed too far in the ear canal, it can cause serious damage, including ruptured eardrum, also known as tympanic membrane perforations (TMP).
Severe TMP can cause facial paralysis and vertigo.
"If a patient is experiencing symptoms such as hearing loss, drainage, dizziness or abnormality in their facial movements they should see a doctor immediately to assess the possible ear damage," says Dr. Darrat.
Study co-author Michael Seidman, M.D., FACS, director of the division of otologic and neurotologic surgery at Henry Ford Hospital, recommends instead of cotton swabs, using these alternatives to clean the inner ear.
Take cool peroxide, hot tap water and mix equally. Be sure it is body temperature and gently irrigate the ear one or two times per month.
Take plain vinegar and water and use four or five drops in the ear once a week.
See a doctor, who can remove ear wax for you.
Try an over-the-counter treatment such as Debrox.
The Henry Ford study included 1,540 patients with a diagnosis of TMP from 2001-2010. Patients with a cotton swab injury were subdivided into two groups: observation and surgery. Successful outcomes were defined as healed TMP, resolution or improvement of vertigo, tinnitus or facial nerve paralysis, and/or closure of the air-bone gap.
A ruptured eardrum can be treated in one of two ways, depending on the severity of the symptoms. The most common method of treatment is observation of the perforation by an otolaryngologist because often times the eardrum will heal on its own within two months. More severe cases are treated with surgery.
While the study found that most cases or ruptured eardrum heal on their own, neurological deficits, such as facial nerve paralysis, require surgical intervention to repair the eardrum.
Surgical intervention proved very successful, with only one patient suffering mild, but improved vertigo.
Dr. Darrat and her colleagues concluded that proper follow-up with a doctor to test hearing after a case of ruptured eardrum is healed is essential to ensure that no hearing loss was caused from the injury.
**Source: Henry Ford Health System
"In the past, many otolaryngologists have wondered if surgery is really necessary to treat a ruptured eardrum. The results of this study show that 97 percent of cases healed on their own within two months, proving that most cases do not require surgery," says Ilaaf Darrat, M.D., an otolaryngologist at Henry Ford Hospital and co-author of the study.
The study is being presented April 29 at the Combined Otolaryngology Spring Meeting in Chicago.
More than half of patients seen in otolaryngology (ear, nose and throat) clinics, regardless of their primary complaint, admit to using cotton swabs to clean their ears. But if the cotton swab is pushed too far in the ear canal, it can cause serious damage, including ruptured eardrum, also known as tympanic membrane perforations (TMP).
Severe TMP can cause facial paralysis and vertigo.
"If a patient is experiencing symptoms such as hearing loss, drainage, dizziness or abnormality in their facial movements they should see a doctor immediately to assess the possible ear damage," says Dr. Darrat.
Study co-author Michael Seidman, M.D., FACS, director of the division of otologic and neurotologic surgery at Henry Ford Hospital, recommends instead of cotton swabs, using these alternatives to clean the inner ear.
Take cool peroxide, hot tap water and mix equally. Be sure it is body temperature and gently irrigate the ear one or two times per month.
Take plain vinegar and water and use four or five drops in the ear once a week.
See a doctor, who can remove ear wax for you.
Try an over-the-counter treatment such as Debrox.
The Henry Ford study included 1,540 patients with a diagnosis of TMP from 2001-2010. Patients with a cotton swab injury were subdivided into two groups: observation and surgery. Successful outcomes were defined as healed TMP, resolution or improvement of vertigo, tinnitus or facial nerve paralysis, and/or closure of the air-bone gap.
A ruptured eardrum can be treated in one of two ways, depending on the severity of the symptoms. The most common method of treatment is observation of the perforation by an otolaryngologist because often times the eardrum will heal on its own within two months. More severe cases are treated with surgery.
While the study found that most cases or ruptured eardrum heal on their own, neurological deficits, such as facial nerve paralysis, require surgical intervention to repair the eardrum.
Surgical intervention proved very successful, with only one patient suffering mild, but improved vertigo.
Dr. Darrat and her colleagues concluded that proper follow-up with a doctor to test hearing after a case of ruptured eardrum is healed is essential to ensure that no hearing loss was caused from the injury.
**Source: Henry Ford Health System
NIH study finds Avastin and Lucentis are equally effective in treating AMD
Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD), is as effective as the Food and Drug Administration-approved drug Lucentis for the treatment of AMD. The report, from the Comparison of AMD Treatments Trials (CATT), was published online in the New England Journal of Medicine on Sunday, May 1, 2011. CATT is funded by the National Eye Institute (NEI), a part of the National Institutes of Health.
"Over 250,000 patients are treated each year for AMD, and a substantial number of them receive Avastin. Given the lack of efficacy data regarding Avastin for AMD treatment, the NEI had an obligation to patients and clinicians to conduct this study," said Paul A. Sieving, M.D., Ph.D., director of the NEI.
AMD is the leading cause of vision loss and blindness in older Americans. In its advanced stages, the wet form of AMD spurs the growth of abnormal blood vessels, which leak fluid and blood into the macula and obscure vision. The macula is the central portion of the retina that allows us to look straight ahead and to perceive fine visual detail. Accumulation of fluid and blood damages the macula, causing loss of central vision. AMD can severely impede mobility and independence. Many patients are unable to drive, read, recognize faces or perform tasks that require hand-eye coordination.
Genentech, the maker of both drugs, originally developed Avastin to prevent blood vessel growth that enables cancerous tumors to develop and spread. In 2004, the FDA approved Avastin for the systemic treatment of metastatic colon cancer. Genentech later developed Lucentis, derived from a protein similar to Avastin, specifically for injection in the eye to block blood vessel growth in AMD.
In 2005, two Genentech-sponsored clinical trials established Lucentis as highly effective for the treatment of wet AMD. During the year between the announcement of the trial results and the release of Lucentis, ophthalmologists began injecting AMD patients with low doses of Avastin, due to its similarity to Lucentis and its availability. The FDA has not licensed Avastin for the treatment of AMD.
Serious adverse events (primarily hospitalizations) occurred at a 24 percent rate for patients receiving Avastin and a 19 percent rate for patients receiving Lucentis. These events were distributed across many different conditions, most of which were not associated with Avastin in cancer clinical trials where the drug was administered at 500 times the dose used for AMD. The number of deaths, heart attacks, and strokes were low and similar for both drugs during the study. CATT was not capable of determining whether there is an association between a particular adverse event and treatment. Differences in serious adverse event rates require further study.
Investigators in the CATT study will continue to follow patients through a second year of treatment. These additional data will provide information on longer-term effects of the drugs on vision and safety.
**Source: NIH/National Eye Institute
"Over 250,000 patients are treated each year for AMD, and a substantial number of them receive Avastin. Given the lack of efficacy data regarding Avastin for AMD treatment, the NEI had an obligation to patients and clinicians to conduct this study," said Paul A. Sieving, M.D., Ph.D., director of the NEI.
AMD is the leading cause of vision loss and blindness in older Americans. In its advanced stages, the wet form of AMD spurs the growth of abnormal blood vessels, which leak fluid and blood into the macula and obscure vision. The macula is the central portion of the retina that allows us to look straight ahead and to perceive fine visual detail. Accumulation of fluid and blood damages the macula, causing loss of central vision. AMD can severely impede mobility and independence. Many patients are unable to drive, read, recognize faces or perform tasks that require hand-eye coordination.
Genentech, the maker of both drugs, originally developed Avastin to prevent blood vessel growth that enables cancerous tumors to develop and spread. In 2004, the FDA approved Avastin for the systemic treatment of metastatic colon cancer. Genentech later developed Lucentis, derived from a protein similar to Avastin, specifically for injection in the eye to block blood vessel growth in AMD.
In 2005, two Genentech-sponsored clinical trials established Lucentis as highly effective for the treatment of wet AMD. During the year between the announcement of the trial results and the release of Lucentis, ophthalmologists began injecting AMD patients with low doses of Avastin, due to its similarity to Lucentis and its availability. The FDA has not licensed Avastin for the treatment of AMD.
Serious adverse events (primarily hospitalizations) occurred at a 24 percent rate for patients receiving Avastin and a 19 percent rate for patients receiving Lucentis. These events were distributed across many different conditions, most of which were not associated with Avastin in cancer clinical trials where the drug was administered at 500 times the dose used for AMD. The number of deaths, heart attacks, and strokes were low and similar for both drugs during the study. CATT was not capable of determining whether there is an association between a particular adverse event and treatment. Differences in serious adverse event rates require further study.
Investigators in the CATT study will continue to follow patients through a second year of treatment. These additional data will provide information on longer-term effects of the drugs on vision and safety.
**Source: NIH/National Eye Institute
EEUU: Campaña para adelgazar con Beyoncé
Beyoncé se ha unido a la lucha de la primera dama de EEUU, Michelle Obama, contra la obesidad infantil. Y para lograr que los niños lleven una alimentación más sana y se muevan, nada mejor que ponerse a bailar con ellos. La cantante ha adaptado su tema 'Move your Body', se ha puesto los pantalones cortos y los calcetines y se ha ido mover el esqueleto al comedor de un colegio.
"Queremos hacer de esto algo divertido", ha reconocido Beyoncé. En el vídeo que ha hecho específicamente para la campaña 'Let's Move', lanzada por Michelle Obama, se la ve en una cafetería escolar donde los niños tienen varios alimentos para elegir, pero pocos se decantan por las frutas y verduras que pregona la mujer del presidente estadounidense.
La Primera Dama se ha tomado como empeño personal que los niños y adolescentes estadounidenses pierdan kilos. Según los datos oficiales de la propia campaña, las tasas de obesidad se han triplicado en el país en las últimas tres décadas; y en la actualidad, uno de cada tres niños es obeso o tiene sobrepeso en EEUU. Las cifras son incluso peores entre las comunidades hispanas y negras, donde el porcentaje alcanza al 40%. Tal vez por eso, los niños de esta procedencia tienen una amplia presencia en el videoclip de la cantante de color.
"Si no resolvemos este problema pronto, un tercio de todos los nacidos después del año 2000 sufrirán diabetes en algún momento de sus vidas", alertan los especialistas, y muchos otros sufrirán otros problemas crónicos, como diabetes, tensión arterial, cáncer o asma.
El sedentarismo de los actuales entretenimientos (como el ordenador o los videojuegos), la escasez de parques y lugares abiertos para que los niños jueguen y corran, y el crecimiento que han experimentado las porciones en los restaurantes y locales de comida rápida tienen la culpa de esta epidemia moderna. Una epidemia a la que no es ajena tampoco España, donde, según las últimas estadísticas dadas a conocer por la Agencia Española de Seguridad Alimentaria y Nutrición (Aesan), el problema podría afectar ya al 30% de nuestros niños.
"Queremos hacer de esto algo divertido", ha reconocido Beyoncé. En el vídeo que ha hecho específicamente para la campaña 'Let's Move', lanzada por Michelle Obama, se la ve en una cafetería escolar donde los niños tienen varios alimentos para elegir, pero pocos se decantan por las frutas y verduras que pregona la mujer del presidente estadounidense.
La Primera Dama se ha tomado como empeño personal que los niños y adolescentes estadounidenses pierdan kilos. Según los datos oficiales de la propia campaña, las tasas de obesidad se han triplicado en el país en las últimas tres décadas; y en la actualidad, uno de cada tres niños es obeso o tiene sobrepeso en EEUU. Las cifras son incluso peores entre las comunidades hispanas y negras, donde el porcentaje alcanza al 40%. Tal vez por eso, los niños de esta procedencia tienen una amplia presencia en el videoclip de la cantante de color.
"Si no resolvemos este problema pronto, un tercio de todos los nacidos después del año 2000 sufrirán diabetes en algún momento de sus vidas", alertan los especialistas, y muchos otros sufrirán otros problemas crónicos, como diabetes, tensión arterial, cáncer o asma.
El sedentarismo de los actuales entretenimientos (como el ordenador o los videojuegos), la escasez de parques y lugares abiertos para que los niños jueguen y corran, y el crecimiento que han experimentado las porciones en los restaurantes y locales de comida rápida tienen la culpa de esta epidemia moderna. Una epidemia a la que no es ajena tampoco España, donde, según las últimas estadísticas dadas a conocer por la Agencia Española de Seguridad Alimentaria y Nutrición (Aesan), el problema podría afectar ya al 30% de nuestros niños.
**Publicado en "EL MUNDO"
El método más eficaz para la prevención de las enfermedades sigue siendo la vacunación
En el marco de la “Semana Europea de la Vacunación” (del 23 al 30 de abril) promovida por la Organización Mundial de la Salud, se celebró ayer una presentación simultánea en 21 ciudades de la Guía “Evidencia científica en vacunas” elaborada por la Organización Médica Colegial de España con el auspicio del Ministerio de Sanidad, Política Social e Igualdad.
Esta guía trata de aportar un conocimiento más científico y exhaustivo sobre el valor de las vacunas, de la protección y prevención que aportan ante las distintas enfermedades en las que su utilización se ha mostrado beneficiosa, y unificar criterios de actuación.
En la inauguración del acto intervinieron Ricard Gutiérrez, vicepresidente de la Organización Médica Colegial (OMC) y Sergio Montero, director general de Sanofi Pasteur MSD.
A través de una mesa redonda, que estuvo moderada por Jesús Lozano, especialista en Medicina Preventiva y director de la Fundación para la Formación de la OMC, intervinieron Angel Gil de Miguel, catedrático de Medicina Preventiva y Salud Pública y Decano de la Facultad de Ciencias de la Salud, de la Universidad Rey Juan Carlos (Madrid) y Ramón Cisterna, catedrático de Microbiología de la Universidad del País Vasco y coordinador del Grupo de Estudio de la Gripe.
En sus intervenciones se puso de manifiesto el valor de las vacunas a través de las últimas evidencias científicas. Angel Gil habló del impacto de la vacunación en el control de las enfermedades transmisibles y Ramón Cisterna se centró en el futuro de las vacunas.
El método más eficaz de todos los tiempos para la prevención
Esta guía trata de aportar un conocimiento más científico y exhaustivo sobre el valor de las vacunas, de la protección y prevención que aportan ante las distintas enfermedades en las que su utilización se ha mostrado beneficiosa, y unificar criterios de actuación.
En la inauguración del acto intervinieron Ricard Gutiérrez, vicepresidente de la Organización Médica Colegial (OMC) y Sergio Montero, director general de Sanofi Pasteur MSD.
A través de una mesa redonda, que estuvo moderada por Jesús Lozano, especialista en Medicina Preventiva y director de la Fundación para la Formación de la OMC, intervinieron Angel Gil de Miguel, catedrático de Medicina Preventiva y Salud Pública y Decano de la Facultad de Ciencias de la Salud, de la Universidad Rey Juan Carlos (Madrid) y Ramón Cisterna, catedrático de Microbiología de la Universidad del País Vasco y coordinador del Grupo de Estudio de la Gripe.
En sus intervenciones se puso de manifiesto el valor de las vacunas a través de las últimas evidencias científicas. Angel Gil habló del impacto de la vacunación en el control de las enfermedades transmisibles y Ramón Cisterna se centró en el futuro de las vacunas.
El método más eficaz de todos los tiempos para la prevención
-En esta videoconferencia se presentó lala nueva guía de evidencia científica sobreel "Valor de las vacunas"
Las vacunas son el método más eficaz de todos los tiempos para la prevención y control de las enfermedades. Además, la regulación a que deben someterse contribuye a garantizar la calidad, eficacia y seguridad de las mismas. De hecho existen muy pocas contraindicaciones y efectos secundarios y la mayoría de ellos son muy poco relevantes clínicamente.
Excepto la potabilización del agua y la invención del frigorífico, no ha existido otro método en toda la historia más eficaz que las vacunas para disminuir la morbi-mortalidad de las enfermedades y mejorar la salud de los ciudadanos y el aumento de la esperanza de vida.
Gracias a ellas se han podido erradicar o tener controladas un gran número de enfermedades. Sin embargo, la drástica disminución de la morbi-mortalidad de las enfermedades vacunables no nos puede llevar a bajar la guardia y dejar de recordar a la población que debe seguir vacunándose. De lo contrario se corre el riesgo de aparición de brotes de enfermedades ya controladas o en vías de desaparición.
Con la edición de esta guía, que ha contado con el apoyo de Sanofi Pasteur MSD, y su presentación simultánea en 21 Colegios de Médicos, se van a facilitar a los profesionales de la medicina unos conocimientos contrastados que permitirán dar una mejor respuesta ante las enfermedades inmunoprevenibles.
En la misma se analiza la evidencia científica sobre las principales vacunas, y para el desarrollo de este acto, cada una de las sedes contará con expertos locales para el posterior desarrollo de la sesión científica. Se facilita así a los profesionales, un instrumento esencial de apoyo a la práctica asistencial diaria junto con los necesarios criterios de valoración sobre el conocimiento que se ha ido acumulando hasta la fecha en este campo.
Las vacunas son el método más eficaz de todos los tiempos para la prevención y control de las enfermedades. Además, la regulación a que deben someterse contribuye a garantizar la calidad, eficacia y seguridad de las mismas. De hecho existen muy pocas contraindicaciones y efectos secundarios y la mayoría de ellos son muy poco relevantes clínicamente.
Excepto la potabilización del agua y la invención del frigorífico, no ha existido otro método en toda la historia más eficaz que las vacunas para disminuir la morbi-mortalidad de las enfermedades y mejorar la salud de los ciudadanos y el aumento de la esperanza de vida.
Gracias a ellas se han podido erradicar o tener controladas un gran número de enfermedades. Sin embargo, la drástica disminución de la morbi-mortalidad de las enfermedades vacunables no nos puede llevar a bajar la guardia y dejar de recordar a la población que debe seguir vacunándose. De lo contrario se corre el riesgo de aparición de brotes de enfermedades ya controladas o en vías de desaparición.
Con la edición de esta guía, que ha contado con el apoyo de Sanofi Pasteur MSD, y su presentación simultánea en 21 Colegios de Médicos, se van a facilitar a los profesionales de la medicina unos conocimientos contrastados que permitirán dar una mejor respuesta ante las enfermedades inmunoprevenibles.
En la misma se analiza la evidencia científica sobre las principales vacunas, y para el desarrollo de este acto, cada una de las sedes contará con expertos locales para el posterior desarrollo de la sesión científica. Se facilita así a los profesionales, un instrumento esencial de apoyo a la práctica asistencial diaria junto con los necesarios criterios de valoración sobre el conocimiento que se ha ido acumulando hasta la fecha en este campo.
**Publicado en "MEDICOS Y PACIENTES"
FARMACÉUTICOS ALMERIENSES ESTUDIAN AL NIÑO MAL COMEDOR
El Colegio Oficial de Farmacéuticos de Almería, en colaboración con Abbott Nutrition, ha organizado una jornada en la que los farmacéuticos almerienses analizaron las causas, comportamientos y consecuencias del niño mal comedor. Según los portavoces del citado Colegio, el objetivo de esta conferencia fue la de dar a conocer la dimensión de los niños que comen mal, profundizando en el tratamiento y comportamiento ante esta situación, así como en el abordaje de este problema desde oficina de farmacia. Así, el nutricionista Gerardo Garcés Escobar, quien es también responsable de Asuntos Científicos en Nutrición Pediátrica de Abbott España, señaló que "la clave para solucionar este problema es fomentar buenos hábitos nutricionales en el niño para promover una alimentación completa y equilibrada".
En estA línea, aclaró que este proceso "no es sencillo, sino más bien largo y complicado, pues se trata de enseñar a comer, es algo educacional. Las pautas a seguir por los padres debe ser una actitud perseverante y paciente, de manera que los niños observen desde un ambiente positivo lo bueno de comer de forma saludable". Igualmente, Garcés Escobar remarcó que es importante tener en cuenta los hábitos nutricionales del hogar, ya que "si los padres no comen adecuadamente, difícilmente podrán inculcar otros hábitos en sus hijos". También recomienda a las familias que eviten todas las distracciones a la hora de la comida, como por ejemplo la televisión.
Según los estudios actuales, el 45 por ciento de los menores en edad preescolar en España comen mal, lo que repercute en su correcto desarrollo tanto físico como cognitivo. Por todo ello, es importante dar a conocer entre los profesionales sanitarios y las familias las claves que pueden corregir dicho problema.
**Publicado en "ACTA SANITARIA"
Subscribe to:
Comments (Atom)